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A constellation of neurologic, respiratory, and gastrointestinal 
symptomologies, not only have the number of diagnostic cases of NAS risen 
over the years but so has the cost associated with the treatment and 
management of this condition. For example, NICU admissions for NAS 
increased in the United States from 7 per 1,000 admissions in 2004 to 27 
per 1,000 admissions in 2012, while the mean hospital charges for babies 
diagnosed with NAS rose from $39,400 in 2000 to $53,400 in 2009 
meanwhile mean hospital charges for all other newborns rose from $6,600 in 
2000 to $9,500 in 2009. The state of Tennessee, and in particular, East 
Tennessee, has one of the highest rates of NAS incidence in the United 
States, and the number of NAS births each year in this part of the country is 
almost two to three times higher compared to number of NAS births in the 
rest of the country.
While multiple research studies have been and are currently being 
conducted on NAS, one aspect of NAS that seems to baffle yet intrigue most 
researchers is that why do only 35-40% of opioid exposed pregnancies 
result in NAS requiring medication while the rest do not. This means that 
there are definitely some discriminatory factors at play in addition to in utero 
opioid exposure, and our objective in this study was to shed light on one of 
those potential discriminatory factors, namely birth weight. 
Therefore, our objective in this study was to use a large sample size 
(N=18,728) to elucidate the relationship between birthweight and NAS 
diagnosis. That is, can high or low birth weight predict the development of 
NAS among newborns prenatally exposed to opioids.
Statistical Analysis & Results Discussion & Implications
All statistical analyses were conducted using SPSS (version 25). Our 
question was whether birth weight predicted the development of NAS among 
newborns prenatally exposed to opioids. The file, which was automatically 
abstracted from the electronic health record, contained all deliveries within 
the Mountain States Health Alliance System over a 5 year period (July 1, 
2011 – June 30, 2016) at all 5 delivery sites in Northeast Tennessee and 
Southwest Virginia, N=18,728. When limited to newborns who had prenatal 
opioid exposure (based on self-report, positive urine drug screen during 
pregnancy or at delivery, or positive cord blood test) and were full term (37+ 
weeks dating based on pregnancy ultrasound), the sample contained 2,392 
newborns.
>3.5kg, with 1712 and 680 
average birth weight with respect to gestational age thresholds and >3.5kg 
being a proxy for high birth weight with respect to gestational age thresholds
To determine control variables, the two birth weight groups were compared 
on the variables in Table 1. Chi square or t-test was used as applicable for 
this analysis; t-test was used for age (continuous variable) and Chi square 
was used for the other variables (which were categorical in nature). Those 
variables that were significant were included in the final logistic regression 
analysis predicting NAS development from grouped birth weight.
This study is a retrospective analysis of all deliveries within the Mountain 
States Health Alliance System over a 5 years period (July 1, 2011 to June 30, 
2016) at all 5 delivery sites in Northeast Tennessee and Southwestern 
Virginia, N=18,728. Out of the 18,728 newborns file, 2,392 newborns were 
identified who had prenatal opioid exposure and were simultaneously full term 
(37+ weeks based on pregnancy ultrasound). The affiliated university 
Institutional Review Board (IRB) approved the study. Informed consent was 
waived as the study included encrypted chart review data and no protected 
health information (PHI). Study participants were identified, and study 
variables obtained, via electronic abstraction from the delivery hospital 
electronic health record systems (EHR). Inclusion criteria for the study were 
available maternal urine drug screen (UDS) at delivery and any opioid 
exposure during pregnancy. All delivery hospitals had a policy of admission 
UDS for pregnant mothers at the time of delivery. Opioid exposure was 
determined via multiple methods, including self-report, positive UDS at 
delivery, existing diagnosis of maternal substance use disorder involving 
opioids (from prenatal records), indication and/or prescription of medication 
assisted treatment, and infant exposure diagnosis or determination that infant 






Maternal age (yrs.) 26.4±5.2 26.6±5.3 1.13 .259
Marital status (% married) 37.8% 49.3% 26.36 <.001
Race (% White) 94.9% 96.9% 4.35 .037
Infant gender (% male) 46.7% 59.0% 29.18 <.001
Pregnancy smoking (%) 59.5% 29.6% 173.09 <.001
Pregnancy benzodiazepine 
use (%)
5.4% 2.1% 11.32 .001
Pregnancy marijuana use (%) 5.4% 1.3% 18.83 <.001
At this stage, when comparing the two birth weight groups on whether or 
not NAS developed, without having doing logistic regression or controlling 
for confounding variables, 
more likely to develop NAS (22.7%) compared to newborns who weighed 
>
To determine whether the relationship between birthweight and the 
development of NAS was a result of pre-existing differences between the 
two birth weight groups, logistic regression analyses were then run 
predicting NAS development from birth weight, while controlling for the 
significant variables in Table 1. Results are presented in Table 2. As can be 
seen, even after controlling for background and other prenatal exposure 
differences, newborns who weighed 3.5kg were nearly twice as likely to 
develop NAS compared to newborns 
Interestingly, we can also see that neonates born through pregnancies 
which involved smoking, benzodiazepine usage, and marijuana usage, had 
a significantly higher chance of developing NAS, independent of each 
other, and birth weight as well as other associated factors.






Marital status .562 1.75 1.36-2.27
Race -.449 .64 .33-1.22
Infant gender .300 1.35 1.07-1.71
Pregnancy smoking 1.49 4.45 3.36-5.91
Pregnancy benzodiazepine use .849 2.34 1.49-3.68
Pregnancy marijuana use .343 1.41 .87-2.30
Birth weight .666 1.95 1.41-2.69
Reference groups: Marital Status—married; Race—white; Gender—female;
Smoking—none; Benzodiazepine use—none; Marijuana use—none; 
Birthweight—> 3.5 kg
Our study helps shed some important light on the discriminatory factors for NAS 
development, with birth weight being a significantly associated clinical factor as 
we now know. That infants born with low or average birth weight (with respect to 
gestational age thresholds) have a higher risk or are almost twice as likely to 
develop NAS compared to infants born with a high birth weight (with respect to 
gestational age thresholds).
Unfortunately, the mechanism for the transport of opioids across the placenta is 
complicated, and poorly understood. There may be a higher bioavailability of 
opioids in low to average birth weight infants with there being more unbound or 
free opioid compounds and metabolites compared to infants of a higher birth 
weight who may potentially have a higher lipid binding of opioids and 
subsequently less bioavailability of the free or unbound compounds and 
metabolites. However, this is more of a speculation rather than a conclusion to 
explain the results our study.
Regardless, we believe that our study has positive implications for the clinical 
diagnosis and management of NAS. Being equipped with this knowledge that 
opioid exposed neonates of low to average birth weight (with respect to 
gestational age thresholds) have a higher risk of developing NAS will allow 
physicians to identify infants with a higher risk for NAS early, and this will 
subsequently lead to better outcomes and reduced severity in cases of NAS.
We would like to acknowledge the Junior League of Johnson City, which provided 
us with a grant to cover some of the costs associated with this project. Other than 
this grant, we have no other conflicts of interest to declare and did not receive any 
other grant or source of funding. 
Conflicts of Interest & Funding
Barg and Simantov (1989). “Developmental profile of kappa, mu, and delta opioid 
receptors in the rat and guinea pig cerebellum.” Dev Neurosci 11: 428-434.
Cleary et al (2012). “Methadone and perinatal outcomes: a prospective cohort study.”   
Addiction 107: 1482-1492.
Dysart et al (2007). “Sequela of preterm versus term infants born to mothers on a
methadone maintenance program: differential course of neonatal abstinence
syndrome." Journal of Perinatal Medicine 35: 344-346.
Milliren et al (2018). “Hospital Variation in Neonatal Abstinence Syndrome Incidence, 
Treatment Modalities, Resource Use, and Costs Across Pediatric Hospitals in
the United States, 2013 to 2016.” Hospital Pediatrics 8: 15-20.
Patrick et al (2015). “Increasing Incidence and Geographic Distribution of Neonatal
Abstinence Syndrome: United States 2009 to 2012.” J Perinatol 35: 650-655.
Ross et al (2015). “Developmental Consequences of Fetal Exposure to Drugs: What 
We Know and What We Still Must Learn.” Neuropsychopharmacology 40: 61-
87.
Syme et al (2004). “Drug Transfer and Metabolism by the Human Placenta.” Clin
Pharmacokinet 43: 487-514.
Tolia et al (2015). “Increasing Incidence of the Neonatal Abstinence Syndrome in U.S.
Neonatal ICUs.” New Engl J Med 372: 2118-2126.
Table 1. Sample characteristics by birthweight group
